 |
 |

Double-blindness Procedures, Rater Blindness, and Ratings of OutcomeObservations From a Controlled Trial
Metin Basoglu, MD, PhD;
Isaac Marks, MD, FRCPsych;
Maria Livanou;
Richard Swinson, MD, FRCPsych
Arch Gen Psychiatry. 1997;54(8):744-748.
Abstract
 |  |
Background We determined whether blindness in a double-blind randomized controlled trial of alprazolam and exposure therapies in patients with panic disorder and agoraphobia was maintained in assessors and patients, what were the factors related to "unblinding," and whether unblinding was associated with clinical outcome.
Method In 129 patients with panic disorder and agoraphobia who were randomized to alprazolamexposure, placebo-exposure, alprazolam-relaxation, or placebo-relaxation conditions, blindness was tested at the end of treatment by the independent assessors' and patients' classification of the treatment condition.
Results Assessors' classifications were correct in 82% of the alprazolam group and 78% of the placebo group; corresponding figures for patients' classifications were 73% and 70%, respectively. Factors associated with unblinding included drug side effects but not assessors' ratings of treatment outcome.
Conclusion Judgment of the validity of the outcome of a randomized controlled trial is easier if the report notes not only the use of a double-blindness procedure but also details how blind the raters remained and how any unblinding affected their ratings of clinical outcome.
Author Affiliations
From the Section of Experimental Psychopathology, Department of Psychiatry, University of London, London, England (Drs Basoglu and Marks and Ms Livanou); and the Department of Psychiatry, Clark Institute of Psychiatry, Toronto, Ontario (Dr Swinson).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Is Acupuncture Analgesia an Expectancy Effect?: Preliminary Evidence Based on Participants' Perceived Assignments in Two Placebo-Controlled Trials
Bausell et al.
Eval Health Prof 2005;28:9-26.
ABSTRACT
Treatment for Major Depression in Managed Care and Fee-for-Service Systems
Am. J. Psychiatry 1998;155:859-860.
FULL TEXT
|